Page last updated: 2024-10-23

bisoprolol and Cardiac Arrest, Sudden

bisoprolol has been researched along with Cardiac Arrest, Sudden in 14 studies

Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.

Research Excerpts

ExcerptRelevanceReference
"Whether all patients with congestive heart failure (CHF) need to reach the target dose of beta-blocker to obtain a benefit in terms of survival remains uncertain."6.71Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). ( Funck-Brentano, C; Jaillon, P; Lechat, P; Mary-Krause, M; Simon, T, 2003)
"Baroreflex sensitivity was assessed in 287 patients with history of myocardial infarction and left ventricular ejection fraction < or =40% by phenylephrine test and was found to be depressed (4."3.72[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction]. ( Bozhko, AA; Kanopskiĭ, SG; Staritskiĭ, AG, 2004)
"The occurrence of sudden cardiac death (SCD) in patients with silent ischemia after myocardial infarction (MI) and the factors facilitating SCD are unknown."2.74Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]). ( Abbate, A; Erne, P; Jamshidi, P; Kobza, R; Pfisterer, M; Schoenenberger, AW; Stuck, AE; Zuber, M, 2009)
"Whether all patients with congestive heart failure (CHF) need to reach the target dose of beta-blocker to obtain a benefit in terms of survival remains uncertain."2.71Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II). ( Funck-Brentano, C; Jaillon, P; Lechat, P; Mary-Krause, M; Simon, T, 2003)
"The heart failure is one of the pathologies with major social and economic impact in the western world."2.44[Chronic heart failure and sudden death: the message of CIBIS-III]. ( Dequarti, MC; Poggio, L; Vanoli, E, 2007)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (21.43)18.2507
2000's8 (57.14)29.6817
2010's1 (7.14)24.3611
2020's2 (14.29)2.80

Authors

AuthorsStudies
Sánez Tähtisalo, H1
Hiltunen, TP1
Kenttä, T1
Junttila, J1
Oikarinen, L1
Virolainen, J1
Kontula, KK1
Porthan, K1
Sirico, G1
Montisci, A1
Secchi, F1
Mantica, M1
Schoenenberger, AW2
Kobza, R1
Jamshidi, P1
Zuber, M2
Abbate, A1
Stuck, AE1
Pfisterer, M2
Erne, P2
Krum, H1
van Veldhuisen, DJ1
Funck-Brentano, C2
Vanoli, E2
Silke, B1
Erdmann, E1
Follath, F1
Ponikowski, P1
Goulder, M1
Meyer, W1
Lechat, P2
Willenheimer, R1
Simon, T1
Mary-Krause, M1
Jaillon, P1
Kanopskiĭ, SG1
Staritskiĭ, AG1
Bozhko, AA1
Kowey, PR1
Burckhardt, D1
Kiowski, W1
Dubach, P1
Resink, T1
Dequarti, MC1
Poggio, L1
Drummond, GA1
Squire, IB1
Kendall, MJ1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Long Term Study on the Possible Beneficial Effects of Catheterised Renal Denervation in Patients With Heart Failure and Left Ventricular Systolic Dysfunction Who Are Already on Standard Medical Therapy.[NCT01870310]50 participants (Anticipated)Interventional2012-06-30Recruiting
Bisoprolol Plasma Residual Concentrations for the Optimization of Drug Management in Heart Failure With Mild to Reduced Ejection Fraction[NCT03644446]81 participants (Anticipated)Observational [Patient Registry]2017-11-02Recruiting
A Multicenter,Randomized, Double Blind, Double Dummy, Parallel Group Study to Compare Effects of Coreg CR and Coreg IR on Left Ventricular End Systolic Volume Index in Subjects With Stable Chronic Heart Failure[NCT00323037]Phase 3318 participants (Actual)Interventional2006-03-31Completed
Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure[NCT00832442]18,240 participants (Anticipated)Observational2008-08-31Enrolling by invitation
The PACE-MI Registry Study - Outcomes of Beta-blocker Therapy After Myocardial Infarction (OBTAIN)[NCT00430612]7,057 participants (Actual)Observational [Patient Registry]2009-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in BNP Levels

(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Interventionpercentage of change (Mean)
Carvedilol Immediate Release-0.88
Carvedilol Controlled Release-0.86

Change From Baseline in Deceleration Time

(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Interventionpercentage of change (Mean)
Carvedilol Immediate Release24.00
Carvedilol Controlled Release53.37

Change From Baseline in Early to Late Atrial Ratio (E:A Ratio)

(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Interventionpercentage of change (Mean)
Carvedilol Immediate Release-0.20
Carvedilol Controlled Release-0.45

Change From Baseline in End Diastolic Dimension (EDD)

(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Interventionpercentage of change (Mean)
Carvedilol Immediate Release-0.33
Carvedilol Controlled Release-0.36

Change From Baseline in End Systolic Dimension (ESD)

(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Interventionpercentage of change (Mean)
Carvedilol Immediate Release-0.76
Carvedilol Controlled Release-0.83

Change From Baseline in Intraventricular Septal Thickness (IVST)

(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Interventionpercentage of change (Mean)
Carvedilol Immediate Release.08
Carvedilol Controlled Release.05

Change From Baseline in Left Ventricular Ejection Fraction (LVEF)

(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Interventionpercentage of change (Mean)
Carvedilol Immediate Release.08
Carvedilol Controlled Release.08

Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV)

(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Interventionpercentage of change (Mean)
Carvedilol Immediate Release-36.61
Carvedilol Controlled Release-42.22

Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)

(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Interventionpercentage of change (Mean)
Carvedilol Immediate Release-18.29
Carvedilol Controlled Release-20.57

Change From Baseline in Left Ventricular End Systolic Volume (LVESV)

(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Interventionpercentage of change (Mean)
Carvedilol Immediate Release-36.61
Carvedilol Controlled Release-43.00

Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI) Characterized by 2-D Echocardiography

Maintenance Visit 3 minus Baseline. Maintenance Visit 3 occurred 24 weeks after entry into the maintenance period. The maintenance period started after completion of a titration period of variable duration. (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

InterventionmL/m^2 (Mean)
Coreg Immediate Release-18.36
Coreg Controlled Release-20.81

Change From Baseline in Left Ventricular Mass (LVM)

(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Interventionpercentage of change (Mean)
Carvedilol Immediate Release9.5
Carvedilol Controlled Release-9.29

Change From Baseline in Posterior Wall Thickness (PWT)

(NCT00323037)
Timeframe: 24 weeks after entry into the maintenance period

Interventionpercentage of change (Mean)
Carvedilol Immediate Release.07
Carvedilol Controlled Release.05

Safety and Tolerability of Coreg CR

SAEs experienced (NCT00323037)
Timeframe: 24 weeks after entry into the maintenance phase (after unblinding)

Interventionnumber of SAEs (Number)
Carvedilol Immediate Release40
Carvedilol Controlled Release35

Drug Dose Tolerability

(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)

,
Interventionsubjects in each treatment group (Number)
Study Entry (10mg Coreg CR, 3.125mg Coreg IR)Maintenance Entry (10mg Coreg CR, 3.125mg Coreg IR)End of Study (10mg Coreg CR, 3.125mg Coreg IR)Study Entry (20mg Coreg CR, 6.25mg Coreg IR)Maintenance Entry (20mg Coreg CR, 6.25mg Coreg IR)End of Study (20mg Coreg CR, 6.25mg Coreg IR)Study Entry (40mg Coreg CR, 12.5mg Coreg IR)Maintenance Entry (40mg Coreg CR, 12.5mg Coreg IR)End of Study (40mg Coreg CR, 12.5mg Coreg IR)Study Entry (80mg Coreg CR, 25mg Coreg IR)Maintenance Entry (80mg Coreg CR, 25mg Coreg IR)End of Study (80mg Coreg CR, 25mg Coreg IR)
Carvedilol Controlled Release8304399162716224114111
Carvedilol Immediate Release79076113162112214116121

Incidence of Hospitalizations

(NCT00323037)
Timeframe: Up to 32 weeks (titration and maintenance phases)

,
Interventionparticipants in each treatment group (Number)
Hospitalization for Heart FailureHospitalization Due to Any CauseHospitalization or Death
Carvedilol Controlled Release62929
Carvedilol Immediate Release63132

Reviews

2 reviews available for bisoprolol and Cardiac Arrest, Sudden

ArticleYear
A review of carvedilol arrhythmia data in clinical trials.
    Journal of cardiovascular pharmacology and therapeutics, 2005, Volume: 10 Suppl 1

    Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bisoprolol; Ca

2005
[Chronic heart failure and sudden death: the message of CIBIS-III].
    Recenti progressi in medicina, 2007, Volume: 98, Issue:12

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents

2007

Trials

5 trials available for bisoprolol and Cardiac Arrest, Sudden

ArticleYear
Sudden cardiac death in patients with silent myocardial ischemia after myocardial infarction (from the Swiss Interventional Study on Silent Ischemia Type II [SWISSI II]).
    The American journal of cardiology, 2009, Jul-15, Volume: 104, Issue:2

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angioplasty, Balloon, Coronary; Antihypertensi

2009
Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial.
    Cardiovascular therapeutics, 2011, Volume: 29, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Chronic Dis

2011
Bisoprolol dose-response relationship in patients with congestive heart failure: a subgroup analysis in the cardiac insufficiency bisoprolol study(CIBIS II).
    European heart journal, 2003, Volume: 24, Issue:6

    Topics: Adrenergic beta-Antagonists; Bisoprolol; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; D

2003
Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study.
    European heart journal, 2007, Volume: 28, Issue:17

    Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Bisoprolol; Death, Su

2007
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial.
    Lancet (London, England), 1999, Jan-02, Volume: 353, Issue:9146

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Bisoprolol; Death, Sudden, Cardiac; Dou

1999

Other Studies

7 other studies available for bisoprolol and Cardiac Arrest, Sudden

ArticleYear
Effect of four classes of antihypertensive drugs on cardiac repolarization heterogeneity: A double-blind rotational study.
    PloS one, 2020, Volume: 15, Issue:3

    Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Antihypertensive Agents; Bisoprolol;

2020
Myotonic dystrophy type 1 and high ventricular vulnerability at the electrophysiological evaluation: ICD yes or not?
    Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology, 2020, Volume: 39, Issue:1

    Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Bisoprolol; Clinical Decision-Making; Death, Sudden,

2020
[Longevity promoting beta blocker. Soon in 1st place in heart failure?].
    MMW Fortschritte der Medizin, 2003, Sep-11, Volume: 145, Issue:37

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Cause of Death; C

2003
[Correction of baroreflex sensitivity impairment and efficacy of prevention of sudden arrhythmic death in patients with postinfarction left ventricular dysfunction].
    Kardiologiia, 2004, Volume: 44, Issue:10

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti

2004
[Beginning therapy of heart failure with beta blockers. Do these patients survive longer?].
    MMW Fortschritte der Medizin, 2005, Sep-29, Volume: 147, Issue:39

    Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bisoprolol; Death, Sudden, Ca

2005
The Cardiac Insufficiency Bisoprolol Study II.
    Lancet (London, England), 1999, Apr-17, Volume: 353, Issue:9161

    Topics: Adrenergic beta-Antagonists; Bisoprolol; Death, Sudden, Cardiac; Heart Failure; Humans

1999
Possible mechanisms of action in the positive effect of beta blockers in heart failure.
    Heart (British Cardiac Society), 1999, Volume: 82 Suppl 4

    Topics: Adrenergic beta-Antagonists; Bisoprolol; Death, Sudden, Cardiac; Heart Failure; Humans; Myocardial I

1999